Insulin Resistance and Atherosclerosis: Implications for Insulin-Sensitizing Agents
Open accessThe DOI matches its Crossref record; 340 of the 344 references it cites were found in a registry or an index.
Abstract
Patients with type 2 diabetes mellitus (T2DM) are at high risk for macrovascular complications, which represent the major cause of mortality. Despite effective treatment of established cardiovascular (CV) risk factors (dyslipidemia, hypertension, procoagulant state), there remains a significant amount of unexplained CV risk. Insulin resistance is associated with a cluster of cardiometabolic risk factors known collectively as the insulin resistance (metabolic) syndrome (IRS). Considerable evidence, reviewed herein, suggests that insulin resistance and the IRS contribute to this unexplained CV risk in patients with T2DM. Accordingly, CV outcome trials with pioglitazone have demonstrated that this insulin-sensitizing thiazolidinedione reduces CV events in high-risk patients with T2DM. In this review the roles of insulin resistance and the IRS in the development of atherosclerotic CV disease and the impact of the insulin-sensitizing agents and of other antihyperglycemic medications on CV outcomes are discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In contrast, as the MAPK pathway has normal sensitivity to insulin, hyperinsulinemia activates the MAPK pathway, promoting vascular smooth muscle cell growth and activating inflammatory pathways, such as IkB/NF-kB and JNK [107,108].”
From Sarcopenic obesity, insulin resistance, and their implications in cardiovascular and metabolic consequences (2020) · cites this paper as [108]
In the citing paper
“These macrophages, in combination with adipocytes and lipid-infiltrated muscle tissues, stimulate the secretion of proinflammatory cytokines, particularly TNF-α and IL-6, while reducing the release of protective adiponectin, thereby evoking systemic chronic inflammation that directly damages the vascular endothelium and, in, turn exacerbates IR and atherosclerosis (56).”
From Sarcopenic obesity: epidemiology, pathophysiology, cardiovascular disease, mortality, and management (2023) · cites this paper as [56]
Citations
Cites
(1993) · New England Journal of Medicine · doi:10.1056/nejm199309303291401 · Cited by 24,667
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Zinman, B., Wanner, C., Lachin, J. M., Fitchett, D., Bluhmki, E., Hantel, S., Mattheus, M., Devins, T., Johansen, O. E., Woerle, H. J., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504720 · Cited by 12,315
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Ahmed, A., Jorna, T., & Bhandari, S. (2016) · Nephron · doi:10.1159/000447068 · Cited by 11,717
The pathogenesis of atherosclerosis: a perspective for the 1990s
Ross, R. (1993) · Nature · doi:10.1038/362801a0 · Cited by 10,630
Prediction of coronary heart disease using risk factor categories
Wilson, P. W. F., D’Agostino, R. B., Levy, D., Belanger, A. M., Silbershatz, H., & Kannel, W. B. (1998) · Circulation · doi:10.1161/01.cir.97.18.1837 · Cited by 9,581
Stratton, I. M. (2000) · BMJ · doi:10.1136/bmj.321.7258.405 · Cited by 9,059
Effects of Intensive Glucose Lowering in Type 2 Diabetes
(2008) · New England Journal of Medicine · doi:10.1056/nejmoa0802743 · Cited by 7,888
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Neal, B., Perkovic, V., Mahaffey, K. W., de Zeeuw, D., Fulcher, G., Erondu, N., Shaw, W., Law, G., Desai, M., & Matthews, D. R. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1611925 · Cited by 7,830
Research works printed but not linked: 1
- Hsueh, 1999, Insulin signals in the arterial wall, J Cardiol, 84, 21, 10.1016/S0002-9149(99)00353-7 · DOI · Paper page
Cited by
Items 101–200 of 535
Gyldenkerne, C., Mæng, M., Kjøller‐Hansen, L., Maehara, A., Zhou, Z., Ben‐Yehuda, O., Bøtker, H. E., Engstrøm, T., Matsumura, M., Mintz, G. S., et al. (2022) · Circulation · doi:10.1161/circulationaha.122.061983 · Cited by 25
Wang, L., Wang, Y., Liu, R., Xu, L., Zhong, W., Li, L., Wang, C., He, C., Fu, C., & Wei, Q. (2022) · Lipids in Health and Disease · doi:10.1186/s12944-022-01738-3 · Cited by 24
Metrnl as a secreted protein: Discovery and cardiovascular research
Miao, Z., Chen, J., Chen, C.-X., Zheng, S., Zhao, H., & Miao, C. (2024) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2024.108730 · Cited by 25
Risk of cardiovascular events associated with pathophysiological phenotypes of type 2 diabetes
Stidsen, J. V., Christensen, D. H., Henriksen, J. E., Højlund, K., Olsen, M. H., Thomsen, R. W., Christensen, L. B., Nielsen, J. S., Olesen, T. B., & Beck‐Nielsen, H. (2022) · European Journal of Endocrinology · doi:10.1530/eje-22-0020 · Cited by 24
Perumalsamy, S., Huri, H. Z., Abdullah, B. M., Mazlan, O., Ahmad, W. A. W., & Vethakkan, S. R. (2023) · Metabolites · doi:10.3390/metabo13030427 · Cited by 25
Qazmooz, H. A., Smesam, H. N., Mousa, R. F., Al‐Hakeim, H. K., & Maes, M. H. J. (2020) · Journal of Trace Elements in Medicine and Biology · doi:10.1016/j.jtemb.2020.126703 · Cited by 24
Keleszade, E., Patterson, M., Trangmar, S. J., Guinan, K. J., & Costabile, A. (2021) · Molecules · doi:10.3390/molecules26030714 · Cited by 28
Li, X., He, Y., Wang, D., & Momeni, M. R. (2024) · Clinical and Experimental Medicine · doi:10.1007/s10238-024-01514-w · Cited by 38
Maffeis, C., Cendon, M., Tomasselli, F., Tommasi, M., Bresadola, I., Fornari, E., Morandi, A., & Olivieri, F. (2020) · European Journal of Clinical Nutrition · doi:10.1038/s41430-020-00822-0 · Cited by 26
Obesity, inflammation, and heart failure: links and misconceptions
Triposkiadis, F. K., Xanthopoulos, A. V., Starling, R. C., & Iliodromitis, E. K. (2021) · Heart Failure Reviews · doi:10.1007/s10741-021-10103-y · Cited by 25
“Endothelial dysfunction, which reflects nitric oxide deficiency, is a characteristic feature of insulin-resistant states, and is a central mechanism linking insulin resistance and atherosclerotic cardiovascular disease at the cellular level [82].”
BackgroundLiu, Z., Bi, D., Huang, Q., Tu, R., Yu, F., Jian, X., & Feng, J. (2023) · Frontiers in Public Health · doi:10.3389/fpubh.2023.1241523 · Cited by 25
Tian, J., Hu, C., Luo, Y., Zhang, Z., Xiong, S., & Liu, H. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01626-7 · Cited by 26
Li, C., Zhao, S., Li, Y., He, S., Jian, W., Liu, Y., Cheng, Z., & Peng, H. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02555-x · Cited by 26
“Insulin resistance (IR) is a pathological state characterized by insulin receptor abnormalities and reduced insulin sensitivity, which disrupts glucose and lipid metabolism, resulting in hyperglycemia, hypertension, dyslipidemia, and other pathologies [4, 5].”
Bai, W., Chen, H., Wan, H., Ye, X., Ling, Y., Xu, J., Guo, X., & He, J. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02499-y · Cited by 23
Pino, A. D., Scicali, R., Marchisello, S., Zanoli, L., Ferrara, V., Urbano, F., Filippello, A., Mauro, S. D., Scamporrino, A., Piro, S., et al. (2021) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2021.08.030 · Cited by 21
Triglyceride-Glucose Index and the Prognosis of Patients with Acute Ischemic Stroke: A Meta-Analysis
Ma, X., Han, Y., Jiang, L., & Li, M. (2022) · Hormone and Metabolic Research · doi:10.1055/a-1853-9889 · Cited by 25
Serhiyenko, V. A., Serhiyenko, L. M., Sehin, V. B., & Serhiyenko, A. A. (2022) · Endocrine Regulations · doi:10.2478/enr-2022-0031 · Cited by 23
Chen, Q., Xiong, S., Zhang, Z., Yu, X., Chen, Y., Ye, T., Yang, S., Qi, L., Chen, X., Liu, H., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02011-2 · Cited by 24
“…dyslipidemia resulting from insulin resistance, characterized by increased plasma triglyceride levels, decreased levels of high-density lipoprotein (HDL), and the presence of small dense low-density lipoproteins (sdLDL) [23–25], also contributes to the formation of atherosclerotic plaques [8].”
BackgroundWang, R., Cheng, X., & Tao, W. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1362667 · Cited by 23
Tsou, P., & Wu, C. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071057 · Cited by 23
Wang, A., Li, Y., Zhou, L., Liu, K., Li, S., Song, B., Gao, Y., Li, Y., Lu, J., Tian, C., et al. (2022) · Frontiers in Neurology · doi:10.3389/fneur.2022.823611 · Cited by 20
Huang, W., Wang, H., Shen, Z., Wang, X., & Yu, X. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1448359 · Cited by 21
“The imbalance between these two pathways can lead to endothelial dysfunction (38, 39) (.”
BackgroundInsulin resistance, vulnerable plaque and stroke risk in patients with carotid artery stenosis
Cao, J., Zhou, D., Yao, Z., Zeng, Y., Zheng, J., Tang, Y., Huang, J., Liu, Z., & Huo, G. (2024) · Scientific Reports · doi:10.1038/s41598-024-81967-x · Cited by 21
Fang, Y., Dou, A., Shen, Y., Li, T., Liu, H., Cui, Y., & Xie, K. (2024) · Lipids in Health and Disease · doi:10.1186/s12944-024-02213-x · Cited by 20
Huo, G., Zheng, J., Cao, J., Zhang, L., Yao, Z., Zeng, Y., Tang, Y., Liu, Z., Tan, Z., & Zhou, D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.037970 · Cited by 202
Huo, G., Yao, Z., Yang, X., Wu, G.-H., Chen, L., & Zhou, D. (2025) · Journal of the American Heart Association · doi:10.1161/jaha.124.039152 · Cited by 23
Lai, H., Deng, C., Liao, C., Tian, R., liu, K., Luo, Z., He, L., Tu, H., & Li, J. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03067-y · Cited by 22
“Insulin resistance (IR) is a well-established patho-physiological cornerstone of various CMDs [6], with key mechanisms involving endothelial dysfunction [7], oxidative stress [8], lipid metabolism dysregulation [9], and inflammatory pathway activation [10].”
Saturated fat ingestion stimulates proatherogenic inflammation in polycystic ovary syndrome
González, F., Considine, R. V., Abdelhadi, O. A., Xue, J., & Acton, A. J. (2021) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00213.2021 · Cited by 21
Oyetoro, R. O., Wiemer, L., Bardhi, O., Louis, M., & Jacob, R. (2023) · Advances in Medicine · doi:10.1155/2023/2955772 · Cited by 22
“Insulin resistance stimulates endothelin-1 production with increased vasoconstriction of the arterial smooth muscle cells and atherogenesis [18, 19].”
Zhang, Y., Xia, Z., Cai, X., Su, X. Y., Jin, A., Mei, L., Jing, J., Wang, S., Meng, X., Li, S., et al. (2023) · Cardiovascular Diabetology · doi:10.1186/s12933-023-02083-0 · Cited by 20
Ma, X., Chu, H., Sun, Y., Cheng, Y., Zhang, D., Zhou, Y., Liu, X., & Wang, Z. (2024) · Scientific Reports · doi:10.1038/s41598-024-69158-0 · Cited by 26
“Importantly, substantial evidence suggests that insulin resistance and its underlying molecular etiology of insulin resistance can explain a major component of the unexplained cardiovascular risk in patients with insulin resistance syndrome, obese non-diabetes, prediabetes, and type 2 diabetes 31 .”
BackgroundInfluentialMetabolic remodeling induced by mitokines in heart failure
Duan, J., Chen, Z., Wu, Y., Zhu, B., Yang, L., & Yang, C. (2019) · Aging · doi:10.18632/aging.102247 · Cited by 17
“It is clear that IR plays an essential role in atherosclerosis and hypertension [46].”
BackgroundDoctors’ views and strategies to improve patients’ adherence to medication
Yfantopoulos, J., Protopapa, M., Chantzaras, A. E., & Yfantopoulos, P. (2021) · HORMONES · doi:10.1007/s42000-021-00294-2 · Cited by 18
Cui, J., Wang, M., Zhang, W., Sun, J., Zhang, Y., Zhao, L., Hong, Z., Li, D., Huang, Y. X., Zhang, N., et al. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01332-w · Cited by 21
“…under-pins a variety of diseases, including diabetes, metabolic syndrome, and atherosclerotic cardiovascular diseases, manifesting as reduced insulin sensitivity in adipocytes, muscle cells, and hepatocytes, alongside the dysregulation of glucose, lipid, and protein metabolism [1, 3, 4].”
BackgroundZhang, S., Cao, C., Han, Y. Y., Hu, H., & Zheng, X. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01339-3 · Cited by 24
Pu, J., Han, J., Yang, J., Yu, L., & Wan, H. (2024) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.4c00371 · Cited by 21
Tan, Z., Zhou, D., Tang, Y., & Huo, G. (2025) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2025.1537774 · Cited by 18
Yang, M., Zhang, X.-G., Ding, Z., Wang, F.-J., Wang, Y., Jiao, C.-Y., & Chen, J.-H. (2020) · BMC Public Health · doi:10.1186/s12889-020-8323-7 · Cited by 18
Preparing for the NASH epidemic: A call to action
Kanwal, F., Shubrook, J. H., Younossi, Z. M., Natarajan, Y., Bugianesi, E., Rinella, M. E., Harrison, S. A., Mantzoros, C. S., Pfotenhauer, K. M., Klein, S., et al. (2021) · Obesity · doi:10.1002/oby.23250 · Cited by 20
Janssen, J. A. M. J. L. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26189191 · Cited by 20
Asplund, O., Thangam, M., Prasad, R. B., Lejonberg, C., Ekström, O., Hakaste, L., Smith, J. G., Rosengren, A. H., Oscarsson, J., Carlsson, B., et al. (2025) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(25)00283-9 · Cited by 32
Wan, Y., Tabung, F. K., Lee, D. H., Fung, T. T., Willett, W. C., & Giovannucci, E. L. (2021) · Diabetes Care · doi:10.2337/dc21-1530 · Cited by 197
Dutt, C., Salles, J. E. N., Joshi, S., Nair, T., Chowdhury, S., Mithal, A., Mohan, V., Kasliwal, R., Sharma, S., Tijssen, J. G. P., et al. (2022) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s333787 · Cited by 19
Pioglitazone in diabetic kidney disease: forgotten but not gone
Papaetis, G. S. (2022) · Archives of Medical Science - Atherosclerotic Diseases · doi:10.5114/amsad/151046 · Cited by 17
“It is expressed in glomerular, mesangial and tubular segments (especially the renal medullary collecting duct), as well as in renal microvasculature [8, 10].”
BackgroundHu, T., Shen, Y., Cao, W., Xu, Y., Wang, Y., Ma, X., & Bao, Y. (2023) · Nutrition & Metabolism · doi:10.1186/s12986-023-00727-2 · Cited by 16
“First, excessive fat accumulation promotes the secretion of pro-inflammatory factors, including TNF-α, IL-6, and IL-1, which upregulate IKK/NF-κB and MAPK pathways to induce cell apoptosis and ultimately contribute to myocardial injury [30, 31].”
BackgroundEpigenetically altered macrophages promote development of diabetes-associated atherosclerosis
Huang, D., Gao, W., Zhong, X., Wu, H., Zhou, Y., Ma, Y., Qian, J., & Ge, J. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1196704 · Cited by 18
Kim, S., Lee, J., Lee, Y., Song, Y., & Linton, J. A. (2023) · Lipids in Health and Disease · doi:10.1186/s12944-023-01857-5 · Cited by 16
“CVD is frequent in individuals with metabolic syndrome, obesity, high IR, and type 2 diabetes mellitus [16, 17].”
BackgroundSerum Isthmin-1 is negatively correlated with HDL-C in type 2 diabetes mellitus
Feng, R.-Q., Xu, M., Feng, R., Zhang, L., Yin, X., Wang, C., & Liu, J. (2023) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2023.108567 · Cited by 16
Obesity: An Impact with Cardiovascular and Cerebrovascular Diseases
Dutta, S., Singhal, A. K., Suryan, V., & Chandra, N. C. (2023) · Indian Journal of Clinical Biochemistry · doi:10.1007/s12291-023-01157-w · Cited by 24
Xu, R., Li, S., Shi, M., Li, Z., Wang, Y., Li, J., Li, Q., Klausen, L. H., Li, A., Zhao, H., et al. (2020) · Nano Today · doi:10.1016/j.nantod.2020.101054 · Cited by 15
Shang, L., Li, F., Zhu, J., Sun, C., & Wang, Y. (2022) · Plant Foods for Human Nutrition · doi:10.1007/s11130-022-01022-w · Cited by 16
Wu, P., Tsai, S., Lee, C., Lin, W., Chin, Y., Huang, H.-L., Seal, D. W., Chen, T., & Lee, C. (2021) · International Journal of Obesity · doi:10.1038/s41366-021-00745-1 · Cited by 17
“Because IR directly promotes the development of atherosclerotic CVD [13], prevention, screening, and intervention targeting children with high IR should be stressed.”
BackgroundInfluentialLin, Y., Tao, J., Han-Yi, W. A. N. G., Guan, H., Liu, X., Dong, X., & Gao, W. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-026-03109-z · Cited by 17
Li, Q., Song, Y., Zhang, Z., Xu, J., Liu, Z., Tang, X., Wang, X., Chen, Y., Zhang, Y., Zhu, P., et al. (2024) · Journal of Diabetes · doi:10.1111/1753-0407.13589 · Cited by 17
Triglyceride–Glucose Index May Predict Renal Survival in Patients with IgA Nephropathy
Qin, A., Tan, J., Wang, S., Dong, L., Jiang, Z., Yang, D., Zhou, H., Zhou, X., Tang, Y., & Qin, W. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11175176 · Cited by 16
“Insulin resistance (IR), an early metabolic complication characterized by impaired responses to insulin in organs and tissues, is strongly predictive of CVD (cardiovascular disease) [3].”
BackgroundLi, T., Jiang, N. S., Kaskey, J., Schnatz, P. F., & Nudy, M. S. (2025) · Climacteric · doi:10.1080/13697137.2025.2509844 · Cited by 19
Tang, H., Wang, K., Zheng, K., Wen, Z., Yang, Y., Nie, X., Liu, Q., & Wang, S. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02914-2 · Cited by 17
Ruskovska, T., & Bernlohr, D. (2023) · Biomedicines · doi:10.3390/biomedicines11092560 · Cited by 19
Liu, Z., Fu, H., Li, N., Deng, F., Gan, Y., Ye, Y., Huang, B., Liu, C., Chen, J., & Li, X. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.118841 · Cited by 20
Estimated Glucose Disposal Rate Associated With Risk of Frailty and Likelihood of Reversion
Hou, D., Liu, S., Sun, Y., Liu, C., Shang, X., Pei, L., & Chen, G. (2025) · Journal of Cachexia Sarcopenia and Muscle · doi:10.1002/jcsm.13814 · Cited by 18
“On the one hand, systemic insulin resistance leads to atherogenic lipid phenotypes by increasing very low-density lipoprotein particles, which are metabolized into residual lipoproteins that promote atherosclerosis [9, 26, 27].”
InfluentialThe Association of Triglyceride Glucose index for Coronary Artery Disease in Postmenopausal Women
Liu, J., Bu, H., Ding, Z., Zhang, Y., Chen, Y., & Gao, Y. (2022) · Clinical and Applied Thrombosis/Hemostasis · doi:10.1177/10760296221094030 · Cited by 13
“Chronic hyperinsulinemia increases the synthesis of very low-density lipoprotein cholesterol, proliferation of vascular smooth muscle cells, transport of LDL cholesterol into arterial smooth muscle cells, and activation of inflammation genes.(24) In addition, IR stimulates the progression of CAD by disrupting glucose…”
BackgroundZhang, Q., Liang, J., Yin, J., Jiang, Y., Yu, N., Liao, X., Zhao, S., Wu, L., & Fan, R. (2022) · Journal of Medical Virology · doi:10.1002/jmv.27977 · Cited by 13
“Insulin resistance and the Framingham risk score, which are associated with T2DM and CVD, were not evaluated in the current study.(27,28) Fourth, the patients in this study were from an Asian population with CHB, and the effect of TDF in patients of other ethnicities (e.”
Shao, X., Tan, Z., Sun, L., Fu, Y., Chen, A., Chen, J., Bai, G., & Zhang, J. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03021-y · Cited by 15
He, D., Huang, Y., Ni, X., & Bao, Z. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03070-3 · Cited by 14
Li, C., Luo, X., Chen, Y., Lin, J., & Gu, S. (2026) · Cardiovascular Diabetology · doi:10.1186/s12933-025-03064-1 · Cited by 18
“This impaired response not only contributes directly to diabetes onset but also induces oxidative stress, systemic inflammation, and endothelial dysfunction, thereby accelerating atherosclerosis and cardiovascular–cerebrovascular disease progression [35–41].”
Melloni, M., Sergi, D., Simioni, C., Passaro, A., & Neri, L. M. (2023) · Biology · doi:10.3390/biology12030449 · Cited by 14
Qian, J., Huang, G., & Mao, Y. (2024) · BMC Public Health · doi:10.1186/s12889-024-19186-2 · Cited by 16
Zhang, S., Fan, T., Wang, L., Chen, N., & Ma, L. (2024) · BMC Infectious Diseases · doi:10.1186/s12879-024-09711-4 · Cited by 14
“Numerous studies have indicated that IR is associated with the prognosis of pathological processes such as cardiovascular and cerebrovascular diseases and other diseases [8–10].”
BackgroundLi, X., Hao, J., Han, Q., Wang, D., Lu, Y., Tu, J., Wang, L., Wang, J., Ning, X., Yang, C., et al. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1444030 · Cited by 13
“No signi fi cant associations were found among men and younger participants after adjusting for confounding factors. dysfunction, and accelerated atherosclerosis — all contributing factors to ischemic stroke (18 – 22).”
BackgroundLi, H., Chen, M., Wang, Y., Cui, W., Lou, Y., Chen, D., Deng, H., & Shen, Z. (2024) · Journal of Inflammation Research · doi:10.2147/jir.s496419 · Cited by 14
“32,33 This may be a potential mechanism causing the development of CHD in patients with T2DM.”
Kwak, J., Han, K., Lee, E. Y., Lee, S.-H., Lim, D., Kwon, H., & Lee, J. (2025) · Endocrinology and Metabolism · doi:10.3803/enm.2024.2205 · Cited by 15
Rachfal, A. W., Grant, S. F. A., & Schwartz, S. S. (2021) · International Journal of General Medicine · doi:10.2147/ijgm.s305156 · Cited by 14
Pala, A. A., & Urcun, Y. S. (2021) · Vascular · doi:10.1177/17085381211018332 · Cited by 13
Rehman, S., Song, J., Faisal, M., Alatar, A. A., Akhter, F., Ahmad, S., & Hu, B. (2021) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2021/6621568 · Cited by 13
Deng, X., Zhao, Z., Zhao, L., Wang, C., Li, Y., Cai, Z., Li, H., Gu, T., Xia, Y., Zhang, Z., et al. (2022) · Clinical Biochemistry · doi:10.1016/j.clinbiochem.2022.04.018 · Cited by 17
Wu, C., Qiu, T., Yuan, W., Shi, Y., Yao, X., Jiang, L., Zhang, J., Yang, G., Liu, X., Bai, J., et al. (2022) · Environmental Toxicology and Pharmacology · doi:10.1016/j.etap.2022.103981 · Cited by 12
Chen, W., Shi, S., Tu, J., Liao, L., Liao, Y., Chen, K., Chen, L., & Huang, R. (2022) · BMC Public Health · doi:10.1186/s12889-022-14257-8 · Cited by 16
“Malnutrition can also cause insulin resistance and low-grade systemic inflammatory response, which can accelerate the progression of coronary atherosclerosis [25, 26].”
BackgroundAssociations of Dynapenic Obesity and Sarcopenic Obesity with the Risk of Complications in COVID-19
Mayoral, L. P.-C., Matias‐Cervantes, C. A., Pérez‐Campos, E., Díaz, C. R., Barrios, L. Á. L., Pina-Canseco, M. D. S., Cruz, M. M., Mayoral, E. P., Solórzano-Mata, C. J., Canales, F. J. R., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158277 · Cited by 14
“Insulin resistance differentially affects the phosphatidylinositol 3-kinase and mitogen-activated protein kinase signaling pathways [80] and activates inflammatory pathways including IκB/nuclear factor κB (NF-κB), and c-Jun N-terminal kinase, which contributes to the development of atherosclerotic cardiovascular disea…”
BackgroundSerum asprosin levels are associated with obesity and insulin resistance in Arab adults
Al‐Daghri, N. M., Alokeel, R. M. I., Alamro, A. A., Ansari, M. G. A., Hussain, S. D., Amer, O. E., Yakout, S. M., Alnaami, A. M., & Sabico, S. (2021) · Journal of King Saud University - Science · doi:10.1016/j.jksus.2021.101690 · Cited by 18
Southam, K., de Sousa, C., Daniel, A., Taylor, B. V., Foa, L. C., & Premilovac, D. (2022) · The Journal of Physiology · doi:10.1113/jp282454 · Cited by 13
Zhao, Z.-W., Liu, C., Zhao, Q., Xu, Y.-K., Cheng, Y., Sun, T., & Zhou, Y. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.1019233 · Cited by 12
Hong, J. H., Moon, J. S., Seong, K., & Lim, S. K. (2023) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2023.110872 · Cited by 13
Armato, J., DeFronzo, R. A., Abdul‐Ghani, M. A., & Ruby, R. (2024) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgae540 · Cited by 13
Self-citationZhou, Y., & Gao, J. (2024) · Frontiers in Endocrinology · doi:10.3389/fendo.2024.1444800 · Cited by 16
Endothelial dysfunction and inflammation in patients with non-obstructive coronary arteries
Pakhtusov, N. N., Iusupova, A. O., Privalova, E. V., Khabarova, N. V., & Belenkov, Y. N. (2021) · Kardiologiia · doi:10.18087/cardio.2021.1.n1423 · Cited by 12
Dapagliflozin Does Not Modulate Atherosclerosis in Mice with Insulin Resistance
Taberner-Cortés, A., Vinué, Á., Herrero-Cervera, A., Aguilar-Ballester, M., Real, J. T., Burks, D. J., Martínez‐Hervás, S., & Navarro, H. G. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21239216 · Cited by 12
“In line with these clinical trials, in the DECLARE–TIMI 58 trial, dapagliflozin treatment reduced the rate of hospitalisation for heart failure and of death by CVD [18].”
BackgroundInfluentialMacrophage immunometabolism in diabetes-associated atherosclerosis
dos Santos, B. G., & Goedeke, L. (2023) · Immunometabolism · doi:10.1097/in9.0000000000000032 · Cited by 11
“In addition, metabolic syndrome is strongly associated with the development of type 2 diabetes (T2D), which is well-known to increase atherosclerosis and the incidence of cardiovascular events [6].”
Yang, J., Wang, Y., Shi, X., Liu, Y., Ge, S., Li, S., Wang, Y., Li, F., Suryawanshi, P., & Chen, W. (2024) · Nutrition in Clinical Practice · doi:10.1002/ncp.11214 · Cited by 13
Le, C., Qin, Y., Wang, Z., Wang, D., Zhong, F., Yang, S., & Liu, J. (2024) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-024-01494-7 · Cited by 14
Sun, X., Wu, Z., Guo, D., Chen, S., Song, C., Ran, X., Liu, L., Zhang, Y., Liu, X., Cao, G., et al. (2025) · Scientific Reports · doi:10.1038/s41598-025-87967-9 · Cited by 13
Fu, C., Li, Y., Gao, X., Gong, Y., Wang, H., Wang, G., Ma, X., Han, B., Liu, S., Zhang, H., et al. (2025) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-025-01636-5 · Cited by 11
Early prediction of postpartum dyslipidemia in gestational diabetes using machine learning models
Jiang, Z., Chen, X., Lai, Y., Liu, J., Ye, X., Chen, P., & Zhang, Z. (2025) · Scientific Reports · doi:10.1038/s41598-025-92299-9 · Cited by 9
“Impaired insulin signaling not only inhibits glucose metabolism but also stimulates the MAPK pathway, directly promoting atherosclerosis 35 .”
Li, J., Jiang, S., Guo, P., lin, W., Yu, J., Xu, L., Li, X., Chen, X., Fang, B., Qian, C., et al. (2025) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2025.108352 · Cited by 11
Peng, W., Li, Z., & Fu, N. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1579879 · Cited by 13
“Defined as a reduced efficiency of insulin in promoting glucose uptake and utilization (12), IR is a key component of metabolic syndrome and is closely associated with a range of metabolic disorders (13, 14).”
Luo, Y., Shu, L., Wang, Y., Zhao, X., Han, M., Liu, Y., Xu, Y. J., & Han, B. (2025) · International Journal of Obesity · doi:10.1038/s41366-025-01909-z · Cited by 15
Cheng, W., Shu, M., Kuang, L., Bai, X., Jia, X., Zhao, Y., Lu, Y., Zhu, L., Wang, L., Zhu, Y., et al. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2023.123836 · Cited by 10
Ferrannini, G., Bacquer, D. D., Erlund, I., Gyberg, V., Kotseva, K., Mellbin, L., Norhammar, A., Schnell, O., Tuomilehto, J. O., Vihervaara, T., et al. (2022) · Diabetes Care · doi:10.2337/dc22-0272 · Cited by 13
Mewborn, E., & Stanfill, A. G. (2023) · Clinical Medicine Insights Cardiology · doi:10.1177/11795468231170779 · Cited by 12
Shi, S., Sun, M., Liu, Y., Jiang, J., & Li, F. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114672 · Cited by 9
Kour, N., Bhagat, G., Singh, S., Bhatti, S. S., Arora, S., Singh, B., & Bhatia, A. (2023) · Journal of Diabetes & Metabolic Disorders · doi:10.1007/s40200-023-01326-x · Cited by 9
“Various researchers have demonstrated a strong correlation between insulin resistance (IR) and the onset and progression of coronary atherosclerosis which can lead to an elevated risk of adverse cardiovascular (CV) outcomes [9–11].”
Metadata
- Authors
- Di Pino, A., & DeFronzo, R. A.
- Affiliations
- Diabetes Division, University of Texas Health Science Center and Texas Diabetes Institute, San Antonio, Texas
- The University of Texas at San Antonio Health Science Center (US)
- Corresponding author
- DeFronzo, Ralph A
- ORCID
- DeFronzo, Ralph A
- Venue
- Endocrine Reviews
- Publisher
- The Endocrine Society
- Published
- 2019-05-03
- Volume
- 40
- Issue
- 6
- Pages
- 1447-1467
- ISSN
- 0163-769X (ISSN-L)
- 1945-7189
- PMC
- PMC7445419
- OpenAlex
- W2945554427
- Cited by
- 535
- References
- 344
- Citations by year
- 2026: 77 · 2025: 117 · 2024: 95 · 2023: 76 · 2022: 89 · 2021: 55 · 2020: 22 · 2019: 4
- FWCI
- 6.54
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Endocrine Reviews (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (DK-24092-38)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Management and Research
- Keywords
- insulin resistance, atherosclerosis, type 2 diabetes, metabolic syndrome, insulin sensitizers, thiazolidinediones, pioglitazone, cardiovascular risk, macrovascular complications, cardiovascular outcome trials, antihyperglycemic medications, cardiometabolic risk factors
- MeSH terms
- Animals, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones, Atherosclerosis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.